蒂尔泽帕提德:一种对2型糖尿病及其他疾病有前途的药物
Palak Dutta1, Yashaank Kumar2, Alexis T Babu3
1General Medicine, Kyiv Medical University, Kyiv, UKR.
Cureus
|June 2, 2023
概括
蒂尔泽帕提德是一种双GIP/GLP-1受体激动剂,显著改善血糖控制,促进2型糖尿病的体重减轻. 它为心血管提供了好处,并且耐受性很好,具有更广泛的治疗应用的潜力.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 2型糖尿病 (T2DM) 仍然是一个重大的全球健康挑战.
- 目前的治疗方法往往需要组合疗法,并且在疗效或副作用方面可能存在局限性.
- 提尔泽帕提德是一种新的治疗方法,针对双重的cretin通路.
研究的目的:
- 审查蒂尔泽帕提德在T2DM管理中的疗效和安全性.
- 总结了SURPASS临床试验第三阶段的研究结果.
- 为了探索蒂尔泽帕提德未来潜在的适用性.
主要方法:
- 从SURPASS 3期临床试验 (SURPASS 1-5) 的数据分析.
- 评估每周一次的皮下蒂尔泽帕提德注射 (5,10,15毫克) 作为单疗法和组合疗法.
- 评估血糖控制,体重减轻和心血管参数.
主要成果:
- 与其他抗糖尿病药物相比,蒂尔泽帕提德证明了剂量依赖的疗效,实现了优越的血糖控制 (降低HbA1c).
- 观察到体重显著减少 (-6.2至-12.9公斤).
- 对脂质样本,血压和内脏脂肪的积极影响,表明心血管益处.
结论:
- 蒂尔泽帕提德是T2DM的有效和耐受性良好的治疗方法,具有显著的血糖和体重管理益处.
- 这种药物对T2DM患者的心血管风险降低有前途.
- 进一步的研究,包括SURMOUNT试验和SURPASS-CVOT研究,将阐明它在肥胖,心力衰竭和NASH中的作用.
相关概念视频
Glucagon-like Receptor Agonists
372
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
372
Oral Hypoglycemic Agents: Biguanides and Glitazones
241
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
241
Diabetes: Management and Pharmacotherapy
319
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
319
Dipeptidyl Peptidase 4 Inhibitors
216
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
216
Diabetes Mellitus: Type 2 and Gestational
2.6K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.6K
Diabetes Mellitus: Overview and Type I Subtype
2.8K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.8K


